Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymosin alpha-1 during postoperative IMRT for lymph node-positive breast cancer
ChiCTR2600131184Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- May 2026
- Modality
- Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of thymosin alpha 1 in breast cancer (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Incidence of grade 3 or higher radiotherapy-induced lymphocytopenia. Planned start May 2026; status: not yet recruiting.
02
Drugs
thymosin alpha 1
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600131184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131184.